Literature DB >> 20044857

Rapid eye movement sleep behavior disorder in women: relevance to general and specialty medical practice.

Cynthia L Bodkin1, Carlos H Schenck.   

Abstract

Rapid eye movement (REM) sleep behavior disorder (RBD) is a treatable parasomnia involving dream-enacting behaviors that is considered to be a male-predominant disorder. However, it is speculated that underrecognition of RBD among female patients in part contributes to the male predominance, probably because women have less aggressive and violent RBD behaviors. We conducted a literature review focused primarily on women with RBD, in which the age of onset of RBD, types of nocturnal behaviors, presence of dream enactment, polysomnographic findings, clinical course, treatment response, male/female ratio, comorbid diagnoses, and medications were tabulated and discussed. RBD was found to primarily affect middle-aged and older women and those with a broad range of neurological disorders. As the link between RBD and neurodegenerative disorders, such as Parkinson's disease, becomes increasingly apparent, including the delayed emergence of parkinsonism in patients initially diagnosed with idiopathic RBD, primary care and specialty physicians should be aware of RBD in women, its potential complications, its excellent response to clonazepam, and its association with neurological disorders and older age groups.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044857     DOI: 10.1089/jwh.2008.1348

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  21 in total

Review 1.  REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management.

Authors:  Lynn Marie Trotti
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

2.  A Prospective Video-Polysomnographic Analysis of Movements during Physiological Sleep in 100 Healthy Sleepers.

Authors:  Ambra Stefani; David Gabelia; Thomas Mitterling; Werner Poewe; Birgit Högl; Birgit Frauscher
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 3.  [REM sleep behavior disorder as a prodromal stage of α-synucleinopathies: symptoms, epidemiology, pathophysiology, diagnosis and therapy].

Authors:  W H Oertel; C Depboylu; M Krenzer; D Vadasz; V Ries; F Sixel-Döring; G Mayer
Journal:  Nervenarzt       Date:  2014-01       Impact factor: 1.214

4.  REM sleep behavior disorder: from epidemiology to heterogeneity.

Authors:  Siu Ping Lam; Jihui Zhang; Yun-Kwok Wing
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

5.  Factors Influencing the Presentation of REM Sleep Behavior Disorder: The Relative Importance of Sex, Associated Neurological Disorder, and Context of Referral to Polysomnography.

Authors:  Paulo Bugalho; Manuel Salavisa
Journal:  J Clin Sleep Med       Date:  2019-11-05       Impact factor: 4.062

6.  REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics.

Authors:  Suk-Hoon Kang; In-Young Yoon; Sang Don Lee; Ji Won Han; Tae Hui Kim; Ki Woong Kim
Journal:  Sleep       Date:  2013-08-01       Impact factor: 5.849

Review 7.  Parasomnias: an updated review.

Authors:  Michael J Howell
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

8.  Treatment outcomes in REM sleep behavior disorder.

Authors:  Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert
Journal:  Sleep Med       Date:  2013-01-23       Impact factor: 3.492

9.  Rapid eye movement sleep behavior disorder in adults younger than 50 years of age.

Authors:  Yo-El S Ju
Journal:  Sleep Med       Date:  2013-01-21       Impact factor: 3.492

10.  Motor events during healthy sleep: a quantitative polysomnographic study.

Authors:  Birgit Frauscher; David Gabelia; Thomas Mitterling; Marlene Biermayr; Deborah Bregler; Laura Ehrmann; Hanno Ulmer; Birgit Högl
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.